摘要
目的 探讨瑞格列奈与格列齐特治疗初诊2型糖尿病的临床效果.方法 选择2021年9月—2023年2月古田县医院收治的80例新确诊为2型糖尿病患者为研究对象.按照随机数表法分为对照组和观察组,各40例.对照组应用格列齐特,观察组应用瑞格列奈,比较两组治疗1个疗程后体质指数、腰围、臀围、血糖、空腹胰岛素、胰岛素抵抗指数、体脂率、糖化血红蛋白水平变化,统计两组治疗期间并发症发生情况.结果 观察组体质指数水平低于对照组,体脂率、腰围与臀围水平小于对照组,差异有统计学意义(P均<0.05).观察组空腹血糖、餐后2 h血糖水平低于对照组,空腹胰岛素水平高于对照组,糖化血红蛋白和胰岛素抵抗指数水平低于对照组,差异有统计学意义(P均<0.05).治疗期间观察组发生恶心呕吐、低血糖、腹痛和便秘的总发生率显著低于对照组,差异有统计学意义(P均<0.05).结论 瑞格列奈治疗初诊2型糖尿病者,可较快地控制体质指数,降低体脂率,维持血糖稳定,且不良反应少,安全性高.
Abstract
Objective To explore the clinical effects of repaglinide and gliclazide in the treatment of first diagnosis of type 2 diabetes mellitus.Methods A total of 80 patients with newly diagnosed type 2 diabetes from September 2021 to February 2023 in Gutian County Hospital were selected as the study objects.They were divided into control group and observation group according to random number table method,40 cases in each group.The control group was treated with gliclazide,and the observation group was treated with repaglinide.After 1 course of treatment,the changes of body mass index,waist circumference,hip circumference,blood glucose,fasting insulin,insulin resistance index,body fat percentage and glycosylated hemoglobin level were compared between the two groups.Results The body index level of observation group was lower than that of control group,and the body fat percentage,waist circum-ference and hip circumference were lower than that of control group,the differences were statistically significant(all P<0.05).Fasting blood glucose and 2-hour postprandial blood glucose levels in observation group were lower than those in control group,fasting insulin levels were higher than those in control group,and glycosylated hemoglobin and insu-lin resistance index levels were lower than those in control group,the differences were statistically significant(all P<0.05).During treatment,the total incidence of nausea and vomiting,hypoglycemia,abdominal pain and constipation in observation group was significantly lower than that in control group,the differences were statistically significant(all P<0.05).Conclusion In the treatment of newly diagnosed type 2 diabetes,repaglinide can quickly control body mass in-dex,reduce body fat percentage,maintain stable blood sugar,and have fewer adverse reactions and high safety.
基金项目
广州护理学会科研立项项目(2021)(A2021046)
维普
万方数据